<HashMap><database>biostudies-literature</database><scores/><additional><submitter>El Fadili M</submitter><funding>This research was funded by the Researchers Supporting Project (No. RSPD2024R566), King Saud University, Riyadh, Saudi Arabia.</funding><funding>King Saud University</funding><pagination>142</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11293250</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>18(1)</volume><pubmed_abstract>Based on a structural family of thirty-two NR2B-selective N-Methyl-D-Aspartate receptor (NMDAR) antagonists, two phenylpiperazine derivatives labeled C37 and C39 were conceived thanks to molecular modeling techniques, as novel NMDAR inhibitors exhibiting the highest analgesic activities (of pIC&lt;sub>50&lt;/sub> order) against neuropathic pain, with excellent ADME-toxicity profiles, and good levels of molecular stability towards the targeted protein of NMDA receptor. Initially, the quantitative structure-activity relationships (QSARs) models were developed using multiple linear regression (MLR), partial least square regression (PLSR), multiple non-linear regression (MNLR), and artificial neural network (ANN) techniques, revealing that analgesic activity was strongly correlated with dipole momen</pubmed_abstract><journal>BMC chemistry</journal><pubmed_title>In silico insights into the design of novel NR2B-selective NMDA receptor antagonists: QSAR modeling, ADME-toxicity predictions, molecular docking, and molecular dynamics investigations.</pubmed_title><pmcid>PMC11293250</pmcid><funding_grant_id>grant no. RSPD2024R566</funding_grant_id><funding_grant_id>No. RSPD2024R566)</funding_grant_id><pubmed_authors>Abuelizz HA</pubmed_authors><pubmed_authors>Kara M</pubmed_authors><pubmed_authors>Mujwar S</pubmed_authors><pubmed_authors>Elhallaoui M</pubmed_authors><pubmed_authors>El Fadili M</pubmed_authors><pubmed_authors>Er-Rahmani S</pubmed_authors><pubmed_authors>Er-Rajy M</pubmed_authors><pubmed_authors>Ajala A</pubmed_authors><pubmed_authors>Bouzammit R</pubmed_authors></additional><is_claimable>false</is_claimable><name>In silico insights into the design of novel NR2B-selective NMDA receptor antagonists: QSAR modeling, ADME-toxicity predictions, molecular docking, and molecular dynamics investigations.</name><description>Based on a structural family of thirty-two NR2B-selective N-Methyl-D-Aspartate receptor (NMDAR) antagonists, two phenylpiperazine derivatives labeled C37 and C39 were conceived thanks to molecular modeling techniques, as novel NMDAR inhibitors exhibiting the highest analgesic activities (of pIC&lt;sub>50&lt;/sub> order) against neuropathic pain, with excellent ADME-toxicity profiles, and good levels of molecular stability towards the targeted protein of NMDA receptor. Initially, the quantitative structure-activity relationships (QSARs) models were developed using multiple linear regression (MLR), partial least square regression (PLSR), multiple non-linear regression (MNLR), and artificial neural network (ANN) techniques, revealing that analgesic activity was strongly correlated with dipole momen</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jul</publication><modification>2026-06-03T00:39:21.163Z</modification><creation>2025-02-19T02:27:15.919Z</creation></dates><accession>S-EPMC11293250</accession><cross_references><pubmed>39085870</pubmed><doi>10.1186/s13065-024-01248-6</doi></cross_references></HashMap>